Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE: 300436)
Health Care · Pharmaceuticals · CN
CN¥93.12
-6.37% today · -38.7% 1Y
Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE: 300436) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.21B and employs 715 people.
Over the last twelve months the share price has lost 38.7%, trading between 79.00 and 156.22.
Tweenvest scores Fujian Cosunter Pharmaceutical Co., Ltd. across four factors: quality 52/100, value 63/100, growth 25/100. Its strongest factor is value.
300436 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.21B
- Revenue (TTM)
- $60.49M
- P/E
- —
- EPS
- -1.35
- Dividend yield
- —
- Beta (5Y)
- 1.19
- 52-week high
- CN¥156.22
- 52-week low
- CN¥79.00
- Avg volume (3M)
- —
- Shares outstanding
- 159.27M
- Employees
- 715
- Next earnings
- —
About Fujian Cosunter Pharmaceutical Co., Ltd.
Established in 2001 and headquartered in Fuzhou, China, Fujian Cosunter Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the pharmaceutical industry. The company is actively involved in the full spectrum of pharmaceutical operations, encompassing the research and development, production, and sale of medicinal products across China. Its core offerings comprise Chinese patent medicines, which are utilized in treating a variety of conditions, including liver ailments, men's health (andrology), cardiovascular disorders, and other therapeutic areas.
- ISIN
- CNE100001YZ0
- Founded
- 2001
- Listed since
- May 4, 2015
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.